Tesamorelin
- Generic Name
- Tesamorelin
- Brand Names
- Egrifta
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 218949-48-5
- Unique Ingredient Identifier
- MQG94M5EEO
- Background
Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection.
- Indication
Tesamorelin acetate is a synthetic analogue of human hypothalamic Growth Hormone Releasing Factor (hGRF) indicated to induce and maintain a reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
- Associated Conditions
- Lipodystrophies
- Associated Therapies
- -
No trials found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath